Is AstraZeneca plc A Better Buy Than BTG plc, Dechra Pharmaceuticals plc And Genus plc?

How does AstraZeneca plc (LON: AZN) stack up against three pharmaceutical peers: BTG plc (LON: BTG), Dechra Pharmaceuticals plc (LON: DPH) and Genus plc (LON: GNS)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Despite being in the midst of coming to terms with the loss of several key, blockbuster drugs, shares in AstraZeneca (LSE: AZN) (NYSE: AZN.US) have performed remarkably well in recent years. For example, after hitting a low of £25.92 in June 2012, they have risen by over 70% in just three years. That’s a stunning rate of growth and, while at least part of that has been a result of bid rumours and bid approaches, it shows that investors in the company are looking at the long term future for the business, rather than its present performance.

Future Potential

Clearly, AstraZeneca remains a long way off its previous levels of profitability. For example, even back in 2011 AstraZeneca was posting earnings per share of £4.85. This is 1.75 times its current level of earnings of £2.77 and shows just how severe its demise has been.

However, with AstraZeneca changing its strategy in recent years and deciding to go on the offensive so as to replace lost sales, its long term future has considerable potential. For example, it has purchased assets such as the other half of its diabetes joint venture with Bristol-Myers Squibb and this forms part of a repositioning of AstraZeneca, as it seeks to focus on illnesses and health problems that represent significant growth areas across the globe in the long run.

For instance, the number of Americans expected to have diabetes in 2050 is set to be 165% higher than in the year 2000, with this trend expected to be followed across much of the developed and developing world. This presents a tremendous opportunity for AstraZeneca to develop drugs to counter the effects of diabetes, with this being just one example of how the company’s pipeline looks set to benefit from being exposed to growth areas over the long run.

Valuation

Despite its share price rise, AstraZeneca still offers good value for money. For example, it trades on a price to earnings (P/E) ratio of just 15.9, which is slightly below the FTSE 100’s P/E ratio of 16. And, while the next couple of years are expected to see its bottom line come under pressure, the company appears to be doing all of the right things to turn its performance around and is set to deliver growth from 2017 onwards.

Sector Peers

Clearly, there are a number of other top notch pharmaceutical companies within the FTSE 350. One prime example is BTG (LSE: BTG). It offers very different characteristics to AstraZeneca, with it being a strong growth play right now, with BTG’s bottom line expected to rise by 25% this year and by a further 50% next year. And, while it does trade on a P/E ratio of 35.7, its price to earnings growth (PEG) ratio of 0.5 indicates that its shares could move much higher.

Similarly, Genus (LSE: GNS) and Dechra (LSE: DPH) are expected to post excellent gains during the next two years. Their earnings are forecast to rise by 30% and 20% respectively during the period, although their PEG ratios of 1.9 and 2.2 respectively indicate that there is far less upside potential than for BTG. As such, BTG seems to be the pick of the three smaller companies.

However, with AstraZeneca’s pipeline on the up and the company having the potential to make further acquisitions, it remains a better buy than BTG. And, with AstraZeneca having bid potential of its own, as well as a very appealing valuation, its future performance could be superb and this makes it a very strong buy at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

The National Grid share price just plunged another 10%. Time to buy?

The National Grid share price is one of the FTSE 100's most stable, and nothing much happens to it? Well,…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Up 15% in 3 months, but I still won’t touch Vodafone shares with a bargepole

Harvey Jones has been shunning Vodafone shares for years. The FTSE 100 stock is finally showing signs of life, but…

Read more »

Growth Shares

This UK stock could be like buying Nvidia in 2021

Jon Smith thinks he's missed the boat with Nvidia shares, but flags up a UK stock that has some very…

Read more »

Businesswoman calculating finances in an office
Investing Articles

The FTSE 100’s Intertek delivers a bullish update — can the share price soar?

I’d describe Intertek as a quality business with a decent dividend income, but will the share price shoot the lights…

Read more »

Market Movers

Up another 10% yesterday, how high can the Nvidia share price go?

Jon Smith talks through the latest results but flags up why further gains could be harder to come by for…

Read more »

Investing For Beginners

Down 43% in a year, I think this value stock is primed for a comeback

Jon Smith flags up why a FTSE 250 share has fallen so much in the recent past, but explains why…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Nvidia stock is stupidly expensive. Or is it?

Nvidia stock's up over 2,000% in the past five years. Christopher Ruane explains why it could be wildly overvalued --…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

The FTSE 100 stock I’ve been buying this week

Stephen Wright thinks the FTSE 100 slipping back this week has offered an opportunity in one of the highest-quality UK…

Read more »